A little more than two months after inking a licensing deal with Sanofi, CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic...
Just months after pulling off a successful IPO, Flexion Therapeutics is left watching its shares plummet after the FDA forced it to halt a trial on its top prospect.
Another day, another biotech IPO. Waltham, MA-based Proteon Therapeutics has joined the queue of biotechs looking to make the leap into Nasdaq, looking to raise some $69 million.
Cambridge, MA, biotech Tokai Pharmaceuticals pulled off a $97.2 million Wall Street debut, raising the money it needs to get its three-in-one treatment for prostate cancer into late-stage development.
The 12th annual Fierce 15 report will be rolling out at the BioPharm America meeting in Boston on Monday just before we go live with the report on the website.
In the midst of its first major foray into treating obesity, Novo Nordisk is liking what it sees in the space, and now the Danish giant plans to hire hundreds of researchers in a gambit to develop new treatments for the global scourge.
Sutro Biopharma has landed another marquee name for its list of development partners for antibody-drug conjugates. Merck KGaA, which has been struggling in the clinic for years, has signed on with the San Francisco-based biotech, offering a $300 million package of milestones along with some unspecified research support.
Gilead Sciences' simtuzumab failed to meet its main goal in a Phase II pancreatic cancer trial, denting the potential of a therapy the company hopes can treat a wide range of malignancies
Sanofi has stepped up with a $45 million down payment on a potential $200 million early-stage deal to develop new drugs for heart muscle disease. The pharma giant inked one if its rare small-biotech collaboration pacts with MyoKardia, a South San Francisco-based biotech that was funded by Third Rock a couple of years ago.
Just a few days after Auxilium Pharmaceuticals put out the word that pressure on the sales side was forcing a restructuring and the elimination of about 200 jobs, Endo has come along with a proposal to buy out the company for about $2.2 billion worth of cash and stock.
The FDA approved a new opioid-induced constipation treatment from partners AstraZeneca and Nektar Therapeutics, shaking off some safety concerns and green-lighting a drug the two hope can bring in billions.
The University of California has been a rich source of innovative new medicines. It's outlicensed the IP behind such standout biotechs as Aragon and Seragon--twin biotech sisters bought out by pharma giants--as well as Kite Pharma, a recent IPO success focused on CAR-T. And now it wants a bigger piece of the action.
A court ruling has saddled biodefense specialist Siga Technologies with debts it cannot pay, the company said, and the biotech is filing for bankruptcy in an effort to keep its doors open long enough for an appeal.
Novo Nordisk bolstered its better-late-than-never case to win FDA approval for a new long-acting insulin, as the drug, Tresiba, met its main goals in a study on children with Type 1 diabetes.
Anxious to prove that U.K. drug regulators aren't as slow and stodgy as they're often accused of being, British officials today announced the first in a new category of experimental drugs to earn the title of "Promising Innovative Medicine."